34results about How to "Inhibit necrosis" patented technology

The invention discloses a spinal cord fusion agent and a preparation method and use thereof. The spinal cord fusion agent disclosed by the invention is prepared from polyethylene glycol, bone mesenchymal stem cells, Schwann cells, glial cell lined derived neurotrophic factor (GDNF), salvianolic acid and nano graphene. Studies show that the use of the spinal cord fusion agent of the invention enables rapid reconnection of divided white matter fiber tracts and gray matter staple fibers to reconstitute spinal integrity and electrical conduction and is capable of recovering motion and sensory functions below the lesion level in a short period of time, thereby effectively reducing the incidence of paraplegia and complications thereof, and no relevant products exist at home and abroad. The spinal cord fusion agent disclosed by the invention can have a wide application prospect clinically.

The invention belongs to the field of synthetic drugs, and relates to an application of geniposide in alleviating side effects of glucocorticoid, and an application of compounds represented by the formula I or pharmaceutically acceptable salts, esters, or prodrugs in preparation of drugs for alleviating side effects of glucocorticoid. The molecular action mechanism of the compounds in alleviatingthe side effects of glucocorticoid drugs has important clinical significance for developing new drugs.

The present invention belongs to the field of biomedicine, and relates to a synthetic method of a glycyrrhetinic acid ester derivative, especially a preparation method of a glycyrrhetinic acid ester derivative shown as a formula I. Specifically, a raw material of R2H contacts with glycyrrhizic acid, glycyrrhizic acid salt or glycyrrhizic acid derivative to generate the glycyrrhetinic acid ester derivative shown as the formula I in the presence of a dehydrating agent of chloride or concentrated sulfuric acid.

The invention discloses a compound ketoconazole lotion for hair. The compound ketoconazole lotion comprises, by weight, 1-2% of ketoconazole, 0.02-0.03% of clobetasol propionate, 20-26.5% of surfactant, 3-7% of cosurfactant, 0.2-0.5% of conditioner, 6-10% of foaming agent, 0.05-0.15% of ethylenediamine tetraacetic acid disodium salt, 0.5-3% of antioxidant, 0.01-0.03% of pigment and the balance purified water. Accessories used in the compound ketoconazole lotion for hair include the surfactant, the cosurfactant, the conditioner, the foaming agent, the antioxidant and the ethylenediamine tetraacetic acid disodium salt serving as the antioxidant synergist, the stabilizer and the softener. A proper number of accessories are matched with the ketoconazole and the clobetasol propionate so that the characters and the performance of the compound ketoconazole lotion for hair can be stable, the antibacterial activity of the ketoconazole and the clobetasol propionate can be brought into full play, in addition, compound ketoconazole lotion does not contain silicone oil or essence, the hair quality can be well conditioned, and the hair follicles cannot be damaged.

The invention discloses a preparation based on autologous tissue. The preparation includes autologous collagen and autologous adipose-derived stem cells. The invention also discloses application of the preparation based on autologous tissue. Breast implants mediated by autologous collagen and autologous adipose-derived stem cells are used in the embodiment of the invention; the autologous adipose-derived stem cells can significantly increase the survival rate of transplanted adipose cells; tissue differentiated from the autologous adipose-derived stem cells combines with the autologous collagen; a cell growth factor that promotes cell growth is further utilized so that absorption, infection and necrosis of transplanted adipose can be effectively inhibited, vascular regeneration of the transplanted adipose tissue can be promoted, the transplanted adipose has high survival rate, and breast forming effect is good. The effective ingredients of the autologous tissue are utilized in the embodiment to carry out tissue filling; the extract is from the autologous tissue of a patient, foreign object response cannot occur, and safety and reliability are good; the preparation has the advantages of good acquisition convenience, rich resources, good filling effect, small wound and the like.

The invention relates to application of a natural compound in relieving glucocorticoid side effects.

The invention discloses a drug for treating acute cerebral infarction. The drug is prepared from the following raw materials in parts by weight: 0.3-0.45 part of musk, 120-180 parts of radix astragali, 0.5-0.75 part of borneol , 6-9 parts of angelica angelica, 6-9 parts of radix paeoniae rubra, 3-4.5 parts of semen persicae, 3-4.5 parts of safflower, 3-4.5 parts of rhizoma chuanxiong and 3-4.5 parts of pheretima. The drug has the efficacies of restoring consciousness, enlightening brain, tonifying vital energy, promoting blood circulation and removing meridian obstruction, is capable of effectively inhibiting nerve dysfunctions such as ischemia, anoxia and necrosis of brain tissues, has very good effects on the treatment of symptoms such as headache, dizziness, facial paralysis, dysphasia,slobbering, hemiplegia, frequent urination or urinary incontinence, has no toxic and side effects and is safe and reliable.

The invention belongs to the technical field of medicines, and particularly relates to an application of BefA protein in preparing a medicament for treating type I diabetes or complications of type Idiabetes. The medicament has an oral dosage form. The oral dosage form is a tablet, powder, suspension, emulsion, capsule, granule, pill, syrup or lemonade. According to the application, oral administration of BefA protein to T1DM mice can alleviate the symptoms of hyperglycemia and weight loss; oral administration of BefA protein can significantly reduce expression of TLR-4 / NF-kappaB, which is consistent with the diabetic inflammatory signal pathway, in the pancreas of T1DM mice; and BefA protein exerts a concentration-dependent inhibition of pancreatic islet cell necrosis and promotes the differentiation and proliferation of pancreatic beta cells.

The invention discloses a bursaphelenchus xylophilus effector protein BxSCD1 and application thereof, and belongs to the technical field of molecular biology. The amino acid sequence of the bursaphelenchus xylophilus effector protein BxSCD1 is as shown in SEQ ID No. 1, and the nucleotide sequence for expressing the protein is as shown in SEQ ID No. 2. The BxSCD1 is mainly located to cytoplasm, cysteine on the 117 site and cysteine on the 153 site take an important effect on structural stability of the BxSCD1, and the BxSCD1 can inhibit cytonecrosis and basic defense response caused by a bursaphelenchus xylophilus primordial associated molecular pattern (PAMP) BxCDP1 in nicotiana benthamiana and host pine trees. According to the invention, the interaction between the bursaphelenchus xylophilus and the host pine trees is discussed from inhibition of the plant immunoreaction by the effector secreted by the bursaphelenchus xylophilus, and the bursaphelenchus xylophilus effector protein BxSCD1 has the important significance for revealing the pathogenesis of the bursaphelenchus xylophilus, early detecting the occurrence of the bursaphelenchus xylophilus disease and the like.

The invention provides a dipeptide derivative and an application of the dipeptide derivative. Particularly, the invention provides an N-substituted 2(1H) dipeptide derivative or a pharmaceutically acceptable salt of the N-substituted 2(1H) dipeptide derivative and a pharmaceutical composition containing the compound. The compound is capable of effectively treating various hepatic failures such as acute hepatic failure and chronic-on-acute hepatic failure.

The invention provides a dipeptide derivative for improving liver function, and its application, specifically an N-substituted 2(1H) dipeptide derivative and its pharmaceutically acceptable salt, and pharmaceutical composition containing the compound. The compound can effectively improve liver function, to lower alanine aminotransferase (ALT), aspartate aminotransferase (AST) and / or total bilirubin (Tbil). The compound can greatly improve survival rate of liver failure patient.

The invention discloses application of collagen targeted vascular endothelial growth factors in old myocardial infarction treatment. In the application, the collagen targeted vascular endothelial growth factors are fused proteins obtained by fusing collagen binding regions at the ends N and / or C of the vascular endothelial growth factors, the vascular endothelial growth factors are proteins shownfrom the first site to the 166th site with the amino acid sequence of SEQ ID No.1, and the collagen binding regions are proteins shown from the 178th site to the 184th site with the amino acid sequence of SEQ ID No.1. It is shown through experiments that the collagen targeted vascular endothelial growth factors have the capacity of being combined with a cell epimatrix and can be specifically combined with an ischemia cardiomyocyte epimatrix, the myocardial ischemic injury repairing effect is improved, the side effects of VEGF high-dosage medicine application can be avoided, and the collagen targeted vascular endothelial growth factors can be used for treating the old myocardial infarction.

The invention relates to an application of berberine in preparation of a drug for treating viral myocarditis diseases caused by coxsackie virus B3. By means of the drug for treating the viral myocarditis diseases caused by the coxsackie virus B3, an effect of anti-CVB3 is achieved and an effect of inhibiting the expression of a proinflammatory factor and a chemotactic factor is significant, so that the berberine can be used for preparing the drug for treating the viral myocarditis diseases. The drug is less in side effects, is high in curative effects and is excellent in application prospect since a drug in the prior art is not satisfied in clinical treatment effects of the treatment, especially of the treatment in the later period of infection, of the viral myocarditis diseases caused by the coxsackie virus B3 (CVB3).

The invention belongs to the field of drug preparation and application, and particularly relates to application of a ribosome S6 kinase inhibitor SL0101 in the preparation of a drug for treating cardiovascular diseases. The invention aims at providing the drug for treating the cardiovascular diseases, wherein the drug contains a substance for performing treatment by taking an orphan nuclear receptor Nr4a3 as a drug target. Preferably, the effective component of the substance comprises the ribosome S6 kinase inhibitor SL0101. The application of the orphan nuclear receptor Nr4a3 as a target in the preparation of a drug for screening the cardiovascular diseases provides a very wide prospect and important significance for drug application of the ribosome S6 kinase inhibitor SL0101.

The invention relates to the technical field of medical preparations for treating scalds, empyrosis and other diseases, in particular to an ointment for treating scalds and a preparation method thereof. The ointment is prepared from, by mass, 40-60 parts of oven earth, 5-15 parts of safflowers, 5-15 parts of peach kernels, 5-15 parts of frankincense boswellia carterii, 5-15 parts of myrrh, 3-8 parts of coptis chinensis, 15-25 parts of radix arnebiae, 5-15 parts of Crinis carbonisatus, 3-8 parts of borneol, 30 parts of antelope's horn and 400-600 parts of sesame oil. The ointment can diminish inflammation, relieve pain, activate collaterals and promote tissue regeneration, is suitable for first-degree and second-degree burn, chemical burns, chronic skin fester, bedsores and other severe and lingering wounds, and is good in treatment effect, and scars are not obvious after wounds are cured.

The invention discloses a combination drug for treating acute viral hepatitis. The combination drug comprises the following active ingredients in parts by weight: 0.01-0.02 part of adefovir, 15-20 parts of rheum officinale, 15-20 parts of liquorice, 15-20 parts of fructus forsythia, 15-20 parts of white atractylodes rhizome, 15-20 parts of herba lysimachiae, 15-20 parts of sculellaria barbata, 15-20 parts of radix curcumae, 15-20 parts of raspberry and 15-20 parts of corn stigma. The preparation method of the combination drug comprises the following steps: performing reflux extraction on the raw materials by 10 times of 80% ethanol, extracting for 2h, filtering, keeping the residues, collecting the ethanol extract, decompressing and recovering the ethanol, further condensing to get a thick paste, performing vacuum or microwave drying to obtain a dry extract; adding 8 times of water to the residues, decocting and extracting for 2 times with each time for 1.5-2h, filtering, combining the water extracts, decompressing and condensing to get the thick paste, performing vacuum or microwave drying to obtain the dry extract; and combining the extracts, smashing, adding the adefovir, adding the starch or dextrin, and mixing uniformly to obtain a tablet, a granule or a capsule, and packaging.

The invention relates to a herbicide special for a soybean field.The herbicide is prepared from, by weight, 10-90 parts of flumioxazin, 1-10 parts of wetting agent, 1-10 parts of dispersing agent and 1-88 parts of carrier.The ingredients are simple, and the herbicide has the advantages of being efficient, low in toxicity, low in residue level, high in activity, low in dosage and the like.The herbicide can be degraded easily in the environment and is safe to afterreap crops, the frequency of application is reduced, and cost is reduced.As a low-toxicity fluorine-containing pesticide, the herbicide can be absorbed by buds and blades of a plant to be transmitted in the body of the plant, so that synthesis of chlorophyll is inhibited, withering, whitening, necrosis and death of sensitive weeds can be achieved quickly, and annual broadleaved weeds and part of grassy weeds in the field of soybean, peanut and orchard are effectively controlled.

The invention discloses a compound ketoconazole lotion for hair. The compound ketoconazole lotion comprises, by weight, 1-2% of ketoconazole, 0.02-0.03% of clobetasol propionate, 20-26.5% of surfactant, 3-7% of cosurfactant, 0.2-0.5% of conditioner, 6-10% of foaming agent, 0.05-0.15% of ethylenediamine tetraacetic acid disodium salt, 0.5-3% of antioxidant, 0.01-0.03% of pigment and the balance purified water. Accessories used in the compound ketoconazole lotion for hair include the surfactant, the cosurfactant, the conditioner, the foaming agent, the antioxidant and the ethylenediamine tetraacetic acid disodium salt serving as the antioxidant synergist, the stabilizer and the softener. A proper number of accessories are matched with the ketoconazole and the clobetasol propionate so that the characters and the performance of the compound ketoconazole lotion for hair can be stable, the antibacterial activity of the ketoconazole and the clobetasol propionate can be brought into full play, in addition, compound ketoconazole lotion does not contain silicone oil or essence, the hair quality can be well conditioned, and the hair follicles cannot be damaged.

The invention discloses a chitosan-polypropylene carbonate composite medical dressing and a preparation method. The present invention uses polypropylene carbonate as the base film of the dressing, which helps to reduce the discharge of medical solid waste and the application of petrochemical products; the air permeability of the polypropylene carbonate film is improved by making holes through the pore-forming agent; Dopamine is used as a bionic bioadhesive to connect hydrophilic and degradable biomaterial chitosan to hydrophobic polypropylene carbonate, and modify it by polydopamine and chitosan to improve its physical properties as a dressing, Biological properties; and using spermidine as a cross-linking agent, on the one hand, chitosan can be better fixed on the surface of PPC through secondary cross-linking, and on the other hand, the bioactive small molecule spermidine is introduced to improve the rejection of the wound Inflammatory response helps to shorten wound repair time and reduce scar formation.

The invention relates to an unguent for treating scalds and preparation and application methods thereof. The unguent comprises the following raw materials in parts by weight: 32-48 parts of glutton fat, 32-48 parts of giant salamander meat, 12-18 parts of sesame oil, 1.6-2.4 parts of rhizoma polygoni cuspidati, 1.6-2.4 parts of radix scutellariae and 0.8-1.2 parts of borneol. The preparation method of the unguent for treating scalds comprises pre-treating raw materials, grinding, fermenting and stirring into a plaster. The application method comprises the step of directly applying the unguent at a scalded wound surface, or after applying the unguent to gauze or making the unguent into ointment gauze, applying to the scalded wound surface. The unguent for treating scalds and the preparation and application methods thereof has the beneficial effects that according to related theories of traditional Chinese medicine that lung governs skin and hair and gallbladder governs balance, the herbs are used together and reasonably compatible to achieve definite curative effects; when applied to a scald, the unguent can relieve pain and prevent infection, also inhibit the scald surface of a patient from necrocytosis and accelerate cell division, is high in efficiency and avoids scars after curing.

The invention discloses a combined medicine for treating acute viral hepatitis, which comprises the following raw materials in parts by weight: 0.01-0.02 parts of adefovir, 15-20 parts of rhubarb, 15-20 parts of licorice, and 15-20 parts of forsythia 20 parts, 15‑20 parts of Atractylodes macrocephala, 15‑20 parts of Desmodium, 15‑20 parts of Banzhilian, 15‑20 parts of Curcuma, 15‑20 parts of raspberry, 15‑20 parts of corn silk. The preparation method of the combined medicine is as follows: firstly, the raw medicinal material is extracted with 10 times the weight of 80% ethanol under reflux, extracted for 2 hours, filtered, the dregs are retained, the ethanol extract is collected, and the ethanol is recovered under reduced pressure, and then further concentrated to a thick paste , vacuum or microwave drying to obtain a dry extract; then add 8 times the weight of water to the dregs to decoct and extract twice, each time for 1.5 to 2 hours, filter, combine the water extracts, concentrate under reduced pressure to a thick paste, vacuum or Microwave drying to obtain dry extracts; combine the obtained extracts, crush them, add adefovir, and then add starch or dextrin to mix evenly, make tablets, granules or capsules, and pack them separately.

The present invention discloses a preparation method of an ointment for treating burns and scalds. The preparation method comprises the following specific material preparation steps: step one, preparing the following raw materials in ratios: 8-19.2 parts by weight of rhizoma polygoni cuspidati, 8-19.2 parts by weight of baical skullcap root, 10-10.5 parts by weight of borneol, 18-22.5 parts by weight of common bletilla tuber, 27.5-30 parts by weight of calcined gypsum, 6-10.5 parts by weight of sulfadiazine, 5.5-10.5 parts by weight of amur corktree bark and 8-16 parts by weight of vaseline; step two, respectively weighing the borneol, baical skullcap root, rhizoma polygoni cuspidati, sulfadiazine, baical skullcap root, common bletilla tuber, calcined gypsum and amur corktree bark according to the parts by weight, and respectively crushing the materials into powder for a standby application; step three, conducting a sieving treatment of the powder obtained in the step two; and step four, conducting particle size detection of the obtained superfine powder obtained in the step three through a submicron microscope. The traditional Chinese medicines are combined according to related theories of Chinese and Western medicine that lung governs skin and hair, and gallbladder governs balance, the compatibility is reasonable, and the ointment is definite in curative effect, and used fortreating the scalds to relieve pain and prevent infection, can also inhibit cell necrosis on burning surface of a patient, accelerates division of cells, and is quick in response and free of scars after healing.

The invention belongs to the technical field of bio-pharmaceuticals and relates to a pharmaceutical composition containing miRNA-873 and application thereof. In a milliliter of the pharmaceutical composition containing miRNA-873, the content of 1,2-dioleoyl-3-trimethylaminepropane is 0.5-25mg, the molar ratio of miRNA-873 to 1,2-dioleoyl-3-trimethylaminepropane is 1:(150-205), the content of DC cholesterol is 0.1-5mg, the content of 1,2-dioleoyl-3-phosphatidyl ethanolamine is 0.1-20mg, the content of polyethylene glycol 2000 is 1-80mg, and the pharmaceutical composition also comprises the balance of phosphate buffer. The pharmaceutical composition is used for treating heart diseases such as myocardial infarction, myocardial ischemial injury, cardiac hypertrophy or myocardial fibrosis; and moreover, the pharmaceutical composition is simple in preparation process, obvious in drug effect, convenient to use and friendly in treatment environment.

The invention relates to a variety of chemically modified long-acting polypeptides and the application of preparing drugs for acute kidney injury or diabetes complicated with nephropathy, belonging to the field of biopharmaceuticals. The first sequence: glutamic acid is modified on any amino acid of the amino acid sequence shown in SEQ ID NO:1, and the glutamic acid is connected to the fatty acid; the second sequence: any amino acid of the amino acid sequence shown in SEQ ID NO:1 Modified glutamic acid, glutamic acid is linked with water-soluble polymer; third sequence: fatty acid is modified on any amino acid of the amino acid sequence shown in SEQ ID NO:1, fatty acid is linked with glutamic acid, glutamic acid is linked with lysine Acid linkage; fourth sequence: the third sequence is linked to the N-terminal of the amino acid sequence shown in SEQ ID NO:1 through succinyl. The chemically modified long-acting polypeptide of the present invention can significantly enhance the binding ability with the receptor APJ, significantly relieve renal dysfunction caused by ischemia-reperfusion injury, relieve diabetes-induced nephropathy, and significantly relieve renal tubular necrosis, inflammation and fibrosis.

The invention discloses an application of chitosan oligosaccharide in improving lower limb ischemia caused by various diseases. The animal experiments show that chitosan oligosaccharide can restore blood perfusion of ischemic animals in lower limbs, promotes capillary angiogenesis, and inhibits the local inflammatory response. The application has positive value for improving limb ischemia, gangrene and inflammation caused by clinical lower limb ischemia.

The invention relates to a compound as a dipeptidyl peptidase-4 (DPP-IV) inhibitor, which can be used for treating all symptoms or diseases that get benefits by inhibiting DPP-IV activity, such as type I and II diabetes, diabetes complications and other related diseases.

The invention belongs to the technical field of bio-pharmaceuticals and relates to a pharmaceutical composition containing miRNA-873 and application thereof. In a milliliter of the pharmaceutical composition containing miRNA-873, the content of 1,2-dioleoyl-3-trimethylaminepropane is 0.5-25mg, the molar ratio of miRNA-873 to 1,2-dioleoyl-3-trimethylaminepropane is 1:(150-205), the content of DC cholesterol is 0.1-5mg, the content of 1,2-dioleoyl-3-phosphatidyl ethanolamine is 0.1-20mg, the content of polyethylene glycol 2000 is 1-80mg, and the pharmaceutical composition also comprises the balance of phosphate buffer. The pharmaceutical composition is used for treating heart diseases such as myocardial infarction, myocardial ischemial injury, cardiac hypertrophy or myocardial fibrosis; and moreover, the pharmaceutical composition is simple in preparation process, obvious in drug effect, convenient to use and friendly in treatment environment.